To explore the role of CD8 T cells in inducing immunity in AML, we used our MLL-AF9 leukemia model with or without CD8 depletion (Fig. 3C), and found that survival was markedly shortened (P < 0.0001) and MLL-AF9 leukemic cells increased (P = 0.006, gating strategy in Supplementary Fig. 4D) in the group receiving anti-CD8 versus anti-IgG1 antibodies (Fig. 3C), thus revealing that CD8 T cells play an indispensable role in anti-AML immunity. This evidence concerns the gene KMT2A and acute myeloid leukemia.